Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 9,718

Document Document Title
WO/2017/112768A1
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the me...  
WO/2017/109855A1
The present invention pertains to: a compound represented by formula [1] or a salt thereof; a germicidal composition including the compound or a salt thereof; a method for controlling plant disease caused by a phytopathogenic microorgani...  
WO/2017/106288A1
Described herein are novel compounds and methods for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).  
WO/2017/105040A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure can provide an organic electrolumine...  
WO/2017/105382A1
The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza- benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide and crystalline forms of salts and/or solvates of 2-(...  
WO/2017/100925A1
Provided herein is a pharmaceutical formulation for delivery of a therapeutic agent having a metal complexation moiety and a solubility in water or a metal ion solution of less than 1 mg/ml. Said formulation comprises the therapeutic age...  
WO/2017/100591A1
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compou...  
WO/2017/093718A1
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin S...  
WO/2017/088746A1
An epidermal growth factor receptor inhibitor as shown in the following formula, a pharmaceutical composition containing the receptor inhibitor, and use of the inhibitor or the pharmaceutical composition as a medicine for preventing and/...  
WO/2017/040993A4
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their u...  
WO/2017/085484A1
The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the ...  
WO/2017/086729A1
The present disclosure relates to an organic electroluminescent compound, an organic electroluminescent material, and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the prese...  
WO/2017/077008A1
The present invention relates to small molecule compounds based on benzopyrimido- or benzoimidazo-thiazin-imine as well as their (synthesis) intermediates and their use as HDAC inhibitors, in particular HDAC8 inhibitors. The present inve...  
WO/2017/073942A1
The present disclosure relates to an electron buffering material, and an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode an...  
WO/2017/069279A1
Provided is a compound that has an effect of inhibiting RIP1 kinase and is useful as a prophylactic or therapeutic agent for Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiples sclerosis, chronic nephropathy, a...  
WO/2017/069275A1
The present invention provides a novel compound having excellent inhibitory action against KAT II, a production method therefor, a use therefor, and a pharmaceutical composition, or the like, that includes the compound. Provided is the c...  
WO/2017/066863A1
The present invention provides compounds of Formula I: wherein Y, AA, W, R3, R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate for...  
WO/2017/029602A3
The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.  
WO/2017/062729A1
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q is and A, R1, m, X1, X2, Y1, Y2, Y3 and R5a are as defined in the disclosure. Also disclosed are compositions conta...  
WO/2017/060406A1
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ in...  
WO/2017/017631A3
The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.  
WO/2017/051276A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined...  
WO/2017/046117A1
Compounds of formula (I) (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modu...  
WO/2017/046739A1
The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds o...  
WO/2017/042834A1
The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceuti...  
WO/2017/040879A1
The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical diso...  
WO/2017/040993A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their u...  
WO/2017/040877A1
The invention provides heterobicyclic pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's dise...  
WO/2017/030892A1
The present invention relates to methods of modulating (for example inhibiting) activity of histone deacetylases (HDACs) and/or treating HDACs - associated diseases including, for example, cancers, inflammatory disorders, neurodegenerati...  
WO/2017/025914A1
Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infe...  
WO/2017/025491A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2017/025916A1
Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infe...  
WO/2017/014323A1
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or...  
WO/2017/010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO/2017/007756A1
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or ...  
WO/2017/004674A1
Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclo...  
WO/2017/007755A1
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a sub...  
WO/2017/007008A1
Provided are novel low-molecular-weight compounds for suppressing the inductive production of MMPs, especially MMP-9, rather than the constitutive production of MMP-2. The present invention pertains to compounds represented by formula (I...  
WO/2017/001307A1
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds for use in t...  
WO/2017/001660A1
The present invention relates to the following compounds, wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.  
WO/2017/002120A1
Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds ar...  
WO/2017/001655A1
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...  
WO/2017/001661A1
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.  
WO/2016/208592A1
The present invention provides: a bicyclic heterocyclic amide derivative that is represented by formula (1), that shows excellent cancer cell sphere forming ability suppressing effect, and that is useful as an orally administrable antitu...  
WO/2016/203347A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutica...  
WO/2016/204261A1
The present invention addresses the problem of providing low-molecular compounds capable of inhibiting Src family kinases. The present invention pertains to a compound represented by general formula (I) or pharmacologically acceptable sa...  
WO/2016/204270A1
The present invention provides a compound represented by formula (I) (in the formula, A1 and A2 each independently indicate a carbon atom or nitrogen atom; X1 indicates a substituted or unsubstituted C1-6 alkyl group or the like; n is an...  
WO/2016/200690A1
Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising ...  
WO/2016/200939A1
Radiofluorinated 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines targeting Fractalkine Receptor (CX3CR1) are disclosed. Methods of imaging CX3CR1-expressing tumors or cells also are disclosed.  
WO/2016/199761A1
Provided is a plant disease control agent manifesting a high control effect against a wide range of plant pathogens. The present invention provides a compound represented by formula (I): [in the formula, each symbol is as defined in the ...  

Matches 251 - 300 out of 9,718